Lincus | Home

Non-nuclease based gene editing for Hutchison-Guilford Progeria

Sponsor: Yale University

Authors: Raman Bahal

2020-04-01 - 2022-03-31

Development of Dual peptide tagged nanoparticle delivery system for the treatment of stroke

Sponsor: American Heart Association/University of Connecticut Health Center

Authors: Raman Bahal

2025-07-01 - 2027-06-30

Site specific genome editing of Hematopoietic stem cells for Hemophilia B gene therapy

Sponsor: Bayer

Authors: Raman Bahal

2018-07-01 - 2019-06-30

Gene editing therapy for Gaucher disease

Sponsor: Yale University

Authors: Raman Bahal

2020-10-01 - 2025-09-30

Targeting microRNAs to the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs

Sponsor: DHHS/NIH/National Institutes of Health/Beth Israel Deaconess Medical Center

Authors: Raman Bahal

2019-07-01 - 2024-06-30

Next generation targeting of oncomiRs for glioblastoma therapy

Sponsor: Sontag Foundation

Authors: Raman Bahal

2022-10-01 - 2026-09-30

Gut microbes upregulate beta-cell miR-204, impair beta-cell function, and promote diabetes

Sponsor: American Diabetes Association/University of Iowa

Authors: Raman Bahal

2020-07-01 - 2022-06-30

Next-generation gamma-PNA-antimiR-122 to rescue endothelial dysfunction and impaired blood pressure decline at rest in diabetes

Sponsor: DHHS/NIH/National Institutes of Health/University of Iowa

Authors: Raman Bahal

2021-09-01 - 2026-08-31

Development of Sequence-unrestricted In Vivo Gene Factors based on Invader Probes

Sponsor: DHHS/NIH/National Institute of General Medical Sciences/University of Idaho

Authors: Raman Bahal

2019-09-01 - 2021-08-31

Tumor targeted inhibition of oncomiR families for melanoma therapy

Sponsor: American Association of Colleges of Pharmacy

Authors: Raman Bahal

2019-02-01 - 2020-01-31

Developing next-generation RNA inhibitors for prostate cancer therapy

Sponsor: DHHS/NIH/National Institutes of Health/Eastern Virginia Medical School

Authors: Raman Bahal

2024-07-01 - 2029-06-30

Next Generation Targeting of Multiple OncomiRs for Lymphoma Therapy

Sponsor: McDonough (Andrew) B+ Foundation

Authors: Raman Bahal

2019-01-01 - 2020-12-31

Next Generation Targeting of OncomiRs for Pediatric Cancer Therapy

Sponsor: Children's Cancer Research Fund

Authors: Raman Bahal

2018-03-01 - 2019-02-28

Kidney targeted RNA therapies for ADPKD

Sponsor: DHHS/NIH/National Institutes of Health/Yale University School of Medicine

Authors: Raman Bahal

2024-07-01 - 2029-06-30

Next Generation Targeting of oncomiRs for Lymphoma Therapy

Sponsor: Health and Environmental Sciences Institute (HESI)

Authors: Raman Bahal

2019-02-01 - 2021-01-31

Site specific gene editing of IDUA mutations as a novel Mucopolysaccharidosis gene therapy

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2019-04-01 - 2024-03-31

Targeted disruption of STAT3 hypertranscription for cancer therapy

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2025-04-01 - 2030-03-31

Employing gamma-PNA technology to inhibit endothelial miR-122 and impede diabetic vasculopathies

Sponsor: DHHS/NIH/National Institutes of Health/University of Iowa

Authors: Raman Bahal

2023-09-01 - 2028-08-31

Cardiac miR-204 remotely governed by microbiota regulates cardiac hypertrophy and dysfunction

Sponsor: DHHS/NIH/National Institutes of Health/University of Iowa

Authors: Raman Bahal

2022-04-01 - 2027-03-31

Spatiotemporal Characterization and Therapeutic Development Against Long Non-coding RNA H19: A Regulator of Transdifferentiation and Tumor Plasticity Causing Lethal Treatment-Resistant Neuroendocrine Prostate Cancer

Sponsor: Prostate Cancer Foundation

Authors: Raman Bahal

2022-09-01 - 2024-08-31

Are you Raman Bahal?

How to update your information.